SOC PHARMACEUTIQUE GUYANAISE : revenue, balance sheet and financial ratios

SOC PHARMACEUTIQUE GUYANAISE is a French company founded 50 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in MATOURY (97351), this company of category GE shows in 2025 a revenue of 43.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SOC PHARMACEUTIQUE GUYANAISE (SIREN 306796533)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2016 2015 2014
Revenue 43 266 035 € 39 206 335 € 36 100 630 € 32 435 726 € 30 291 338 € 30 139 848 € 29 887 962 € 36 297 593 € 29 118 137 € 29 290 302 € 30 105 670 €
Net income 1 742 907 € 1 714 082 € 1 180 611 € 128 117 € 859 249 € 732 422 € 873 081 € 641 211 € 1 511 707 € -125 774 € 887 463 €
EBITDA 2 509 231 € 2 052 486 € 1 587 345 € 1 443 735 € 1 221 401 € 1 039 826 € 1 425 310 € 2 335 561 € 2 047 917 € 1 208 702 € 1 379 572 €
Net margin 4.0% 4.4% 3.3% 0.4% 2.8% 2.4% 2.9% 1.8% 5.2% -0.4% 2.9%

Revenue and income statement

In 2025, SOC PHARMACEUTIQUE GUYANAISE achieves revenue of 43.3 M€. Revenue is growing positively over 11 years (CAGR: +3.4%). Vs 2024, growth of +10% (39.2 M€ -> 43.3 M€). After deducting consumption (36.4 M€), gross margin stands at 6.8 M€, i.e. a rate of 16%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 2.5 M€, representing 5.8% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 1.7 M€, i.e. 4.0% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2025) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

43 266 035 €

Gross margin (2025) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

6 822 714 €

EBITDA (2025) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

2 509 231 €

EBIT (2025) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

2 539 270 €

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

1 742 907 €

EBITDA margin (2025) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

5.8%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 10%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 49%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.4 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 4.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

9.596%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

48.719%

Cash flow / Revenue (2025) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

3.966%

Repayment capacity (2025) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.381

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

52.8%

Solvency indicators evolution
SOC PHARMACEUTIQUE GUYANAISE

Sector positioning

Debt ratio
9.6 2025
2023
2024
2025
Q1: 0.0
Med: 3.67
Q3: 28.55
Average

In 2025, the debt ratio of SOC PHARMACEUTIQUE GUYANAISE (9.60) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
48.72% 2025
2023
2024
2025
Q1: 26.28%
Med: 43.48%
Q3: 62.04%
Good

In 2025, the financial autonomy of SOC PHARMACEUTIQUE GUYANAISE (48.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
0.38 years 2025
2023
2024
2025
Q1: 0.0 years
Med: 0.0 years
Q3: 0.67 years
Average -6 pts over 3 years

In 2025, the repayment capacity of SOC PHARMACEUTIQUE GUYANAISE (0.38) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 179.81. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 17.3x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

179.808

Interest coverage (2025) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

17.338

Liquidity indicators evolution
SOC PHARMACEUTIQUE GUYANAISE

Sector positioning

Liquidity ratio
179.81 2025
2023
2024
2025
Q1: 147.44
Med: 215.05
Q3: 310.05
Average -8 pts over 3 years

In 2025, the liquidity ratio of SOC PHARMACEUTIQUE GUYANAISE (179.81) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
17.34x 2025
2023
2024
2025
Q1: 0.0x
Med: 0.36x
Q3: 5.44x
Excellent

In 2025, the interest coverage of SOC PHARMACEUTIQUE GUYANAISE (17.3x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 84 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 73 days. The company must finance 11 days of gap between collections and payments. Inventory turnover is 70 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 130 days of revenue, i.e. 15.7 M€ to permanently finance.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

15 668 362 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

84 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

73 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

70 j

WCR in days of revenue (2025) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

130 j

WCR and payment terms evolution
SOC PHARMACEUTIQUE GUYANAISE

Positioning of SOC PHARMACEUTIQUE GUYANAISE in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of SOC PHARMACEUTIQUE GUYANAISE is estimated at 3 933 837 € (range 2 025 518€ - 12 633 263€). With an EBITDA of 2 509 231€, the sector multiple of 0.7x is applied. The price/revenue ratio is 0.21x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
124 transactions
2025k€ 3933k€ 12633k€
3 933 837 € Range: 2 025 518€ - 12 633 263€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
2 509 231 € × 0.7x
Estimation 1 766 210 €
834 951€ - 6 428 361€
Revenue Multiple 30%
43 266 035 € × 0.21x
Estimation 9 214 558 €
4 996 836€ - 27 911 047€
Net Income Multiple 20%
1 742 907 € × 0.8x
Estimation 1 431 825 €
544 963€ - 5 228 845€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare SOC PHARMACEUTIQUE GUYANAISE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about SOC PHARMACEUTIQUE GUYANAISE

What is the revenue of SOC PHARMACEUTIQUE GUYANAISE ?

The revenue of SOC PHARMACEUTIQUE GUYANAISE in 2025 is 43.3 M€.

Is SOC PHARMACEUTIQUE GUYANAISE profitable?

Yes, SOC PHARMACEUTIQUE GUYANAISE generated a net profit of 1.7 M€ in 2025.

Where is the headquarters of SOC PHARMACEUTIQUE GUYANAISE ?

The headquarters of SOC PHARMACEUTIQUE GUYANAISE is located in MATOURY (97351), in the department Guyane.

Where to find the tax return of SOC PHARMACEUTIQUE GUYANAISE ?

The tax return of SOC PHARMACEUTIQUE GUYANAISE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SOC PHARMACEUTIQUE GUYANAISE operate?

SOC PHARMACEUTIQUE GUYANAISE operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.